دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Ending on a Crescendo: Reflections on Seven Years of a Successful Journal
Jadwiga A. Wedzicha 1*, Laurent Brochard 2*, Gavin C. Donaldson 1*, Fernando D. Martinez 3*, and Fernando J. Martinez 4*
doi : 10.1164/rccm.202111-2478ed
Volume 204, Issue 12, pp: 1351–1352
The Upper Airway Microbiome and Lung Injury in COVID-19
John E. McGinniss and Ronald G. Collman
doi : 10.1164/rccm.202109-2226ed
Volume 204, Issue 12, pp: 1353–1355
Reducing Ventilator-associated Brain Injury by Diaphragm Neurostimulation: Racking the Diaphragm to Protect the Brain?
Martin Dres 1,2 and Gianluigi Li Bassi 3,4,5,6
doi : 10.1164/rccm.202110-2312ed
Volume 204, Issue 12, pp: 1355–1357
T–Follicular Helper–like Cells in Sarcoidosis: Lending a Helping Hand
Shaikh M. Atif 1 and Andrew P. Fontenot 2,3
doi : 10.1164/rccm.202109-2139ed
Volume 204, Issue 12, pp: 1357–1359
Cell Therapy with the Cell or without the Cell for Premature Infants?: Time Will Tell
Bernard Thébaud 1,2,3 and Michael A. Matthay 4
doi : 10.1164/rccm.202109-2070ed
Volume 204, Issue 12, pp: 1359–1361
Matrix Metalloproteinase-8 in Pulmonary Hypertension: The Sheep in the Wolf’s Skin?
Elena A. Goncharova 1, Tatiana V. Kudryashova 1, Giovanni Maroli 2, and Soni S. Pullamsetti 2
doi : 10.1164/rccm.202109-2144ed
Volume 204, Issue 12, pp: 1361–1363
New Insights into the Limitations of Host Transcriptional Biomarkers of Tuberculosis
Mahdad Noursadeghi 1 and Rishi K. Gupta 2
doi : 10.1164/rccm.202109-2146ed
Volume 204, Issue 12, pp: 1363–1365
Double Trouble: Airflow and Pulmonary Vascular Obstruction
Michael H. Lee 1,2, Brian B. Graham 1,2, and Todd M. Bull 3
doi : 10.1164/rccm.202109-2153ed
Volume 204, Issue 12, pp: 1365–1367
Outpatient Respiratory Management of Infants, Children, and Adolescents with Post-Prematurity Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline
A. Ioana Cristea , Clement L. Ren , Reshma Amin , Laurie C. Eldredge , Jonathan C. Levin , Parevi P. Majmudar , Anne E. May , Rebecca S. Rose , Michael C. Tracy , Karen F. Watters , Julian Allen , Eric D. Austin , Mary E. Cataletto , Joseph M. Collaco , Robert J. Fleck , Andrew Gelfand , Don Hayes Jr., Marcus H. Jones , Sheila S. Kun , Erica W. Mandell , Sharon A. McGrath-Morrow , Howard B. Panitch , Rizwana Popatia , Lawrence M. Rhein , Alejandro Teper , Jason C. Woods , Narayan Iyer , and Christopher D. Baker ; on behalf of the American Thoracic Society Assembly on Pediatrics
doi : 10.1164/rccm.202110-2269st
Volume 204, Issue 12, pp: e115–e133
Premature birth affects millions of neonates each year, placing them at risk for respiratory disease due to prematurity. Bronchopulmonary dysplasia is the most common chronic lung disease of infancy, but recent data suggest that even premature infants who do not meet the strict definition of bronchopulmonary dysplasia can develop adverse pulmonary outcomes later in life. This post-prematurity respiratory disease (PPRD) manifests as chronic respiratory symptoms, including cough, recurrent wheezing, exercise limitation, and reduced pulmonary function. This document provides an evidence-based clinical practice guideline on the outpatient management of infants, children, and adolescents with PPRD.
Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Mortality in COVID-19
Lili Ren 1,2*, Yeming Wang 3,4*, Jiaxin Zhong 5,6*, Xia Li 7, Yan Xiao 1,2, Jie Li 8, Jing Yang 5,6, Guohui Fan 9, Li Guo 1,2, Zijie Shen 5,6, Lu Kang 5,6, Leisheng Shi 5,6, Qiong Li 8, Jizhou Li 8, Lin Di 10, Haibo Li 3,11, Conghui Wang 1, Ying Wang 1, Xinming Wang 1, Xiaohui Zou 3,11, Jian Rao 1,2, Li Zhang 5,6, Jianbin Wang 8, Yanyi Huang 10,12, Bin Cao 3,4,11,13‡, Jianwei Wang 1,2‡, and Mingkun Li 5,6,14‡
doi : 10.1164/rccm.202103-0814oc
Volume 204, Issue 12, pp: 1379–1390
Alteration of human respiratory microbiota had been observed in coronavirus disease (COVID-19). How the microbiota is associated with the prognosis in COVID-19 is unclear.
Follicular Helper–like T Cells in the Lung Highlight a Novel Role of B Cells in Sarcoidosis
Laura Bauer 1,2*, Lisa Jasmin Müller 2*, Sarah M. Volkers 3, Frederik Heinrich 4, Mir-Farzin Mashreghi 4, Clemens Ruppert 5,6, Leif E. Sander 3,6, and Andreas Hutloff 1,2,7
doi : 10.1164/rccm.202012-4423oc
Volume 204, Issue 12, pp: 1403–1417
Pulmonary sarcoidosis is generally presumed to be a T-helper cell type 1– and macrophage-driven disease. However, mouse models have recently revealed that chronically inflamed lung tissue can also comprise T follicular helper (Tfh)-like cells and represents a site of active T-cell/B-cell cooperation.
Extracellular Vesicles Protect the Neonatal Lung from Hyperoxic Injury through the Epigenetic and Transcriptomic Reprogramming of Myeloid Cells
Gareth R. Willis 1,2, Monica Reis 1,2, Ali Hashemi Gheinani 3,4,5, Angeles Fernandez-Gonzalez 1,2, Elizabeth S. Taglauer 1,2, Vincent Yeung 1,2, Xianlan Liu 1, Maria Ericsson 6, Eric Haas 7, S. Alex Mitsialis 1,2*, and Stella Kourembanas 1,2*
doi : 10.1164/rccm.202102-0329oc
Volume 204, Issue 12, pp: 1418–1432
Mesenchymal stem/stromal cell (MSC)–small extracellular vesicle (MEx) treatment has shown promise in experimental models of neonatal lung injury. The molecular mechanisms by which MEx afford beneficial effects remain incompletely understood.
A Novel Protective Role for Matrix Metalloproteinase-8 in the Pulmonary Vasculature
Paul B. Dieffenbach 1*, Christina Mallarino Haeger 1*, Rakhshinda Rehman 1*, Alexis M. Corcoran 1, Anna Maria F. Coronata 1, Shamsudheen K. Vellarikkal 2, Izabela Chrobak 3, Aaron B. Waxman 1, Sally H. Vitali 4, Lynette M. Sholl 5, Robert F. Padera 5, David Lagares 6, Francesca Polverino 1‡, Caroline A. Owen 1§, and Laura E. Fredenburgh 1
doi : 10.1164/rccm.202108-1863oc
Volume 204, Issue 12, pp: 1433–1451
Mechanical signaling through cell–matrix interactions plays a major role in progressive vascular remodeling in pulmonary arterial hypertension (PAH). MMP-8 (matrix metalloproteinase-8) is an interstitial collagenase involved in regulating inflammation and fibrosis of the lung and systemic vasculature, but its role in PAH pathogenesis remains unexplored.
Endotyping Sleep Apnea One Breath at a Time: An Automated Approach for Separating Obstructive from Central Sleep-disordered Breathing
Ankit Parekh 1, Thomas M. Tolbert 1, Anne M. Mooney 1, Jaime Ramos-Cejudo 2, Ricardo S. Osorio 2, Marcel Treml 3, Simon-Dominik Herkenrath 3, Winfried J. Randerath 3, Indu Ayappa 1, and David M. Rapoport 1
doi : 10.1164/rccm.202011-4055oc
Volume 204, Issue 12, pp: 1452–1462
Determining whether an individual has obstructive or central sleep apnea is fundamental to selecting the appropriate treatment.
Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis
Humphrey Mulenga 1*, Munyaradzi Musvosvi 1*, Simon C. Mendelsohn 1*, Adam Penn-Nicholson 1, Stanley Kimbung Mbandi 1, Andrew Fiore-Gartland 2, Michèle Tameris 1, Simbarashe Mabwe 1, Hadn Africa 1, Nicole Bilek 1, Fazlin Kafaar 1, Shabaana A. Khader 3, Balie Carstens 1, Katie Hadley 1, Chris Hikuam 1, Mzwandile Erasmus 1, Lungisa Jaxa 1, Rodney Raphela 1, Onke Nombida 1, Masooda Kaskar 1, Mark P. Nicol 4,5, Slindile Mbhele 4, Judi Van Heerden 4, Craig Innes 6, William Brumskine 6, Andriëtte Hiemstra 7, Stephanus T. Malherbe 7, Razia Hassan-Moosa 8,9, Gerhard Walzl 7, Kogieleum Naidoo 8,9, Gavin Churchyard 6,10, Mark Hatherill 1, Thomas J. Scriba 1, and the CORTIS Study Team
doi : 10.1164/rccm.202103-0548oc
Volume 204, Issue 12, pp: 1463–1472
Performance of blood transcriptomic tuberculosis (TB) signatures in longitudinal studies and effects of TB-preventive therapy and coinfection with HIV or respiratory organisms on transcriptomic signatures has not been systematically studied.
Options to Minimize the Use of Central Lines: Midodrine, Peripheral Venous Lines, and Midline Catheters
Rania Farhat , Jennifer Minoff , Shannon Burke , and Setu Patolia
doi : 10.1164/rccm.202103-0685rr
Volume 204, Issue 12, pp: 1473–1475
Endobronchial Clear-Cell Sugar Tumor
Chang-Hui Xiao 1, Xian-Zheng Tan 1, Gong-Xun Xie 2, Peng Liu 1, and Jian-Bin Liu 1
doi : 10.1164/rccm.202102-0332im
Volume 204, Issue 12, pp: 1476–1477
Autoimmune Pulmonary Alveolar Proteinosis: Evidence of the Pathogenicity of GM-CSF Antibodies
Aurélie Le Gal 1, Alexandre Chabrol 1, Anne-Laure Brun 2, Séverine Fraboulet 1, Louis-Jean Couderc 1,3,4, and Hélène Salvator 1,3,4
doi : 10.1164/rccm.202101-0073im
Volume 204, Issue 12, pp: e134–e135
Evolution of Obstructive Lung Function in Advanced Pulmonary Arterial Hypertension
Farbod N. Rahaghi 1, Megan Trieu 2, Faisal Shaikh 2, Fereidoun Abtin 2, Alejandro A. Diaz 1, Lloyd L. Liang 2, Igor Barjaktarevic 2, Richard N. Channick 2, Raúl San José Estépar 1, George R. Washko 1, and Rajan Saggar 2*
doi : 10.1164/rccm.202105-1169le
Volume 204, Issue 12, pp: 1478–1481
Evaluating Approaches to Improve Equity in Critical Care Resource Allocation in the COVID-19 Pandemic
Katherine Ross-Driscoll 1, Gregory Esper 1, Kathy Kinlaw 1, Yi-Ting Hana Lee 1, Alanna A. Morris 1, David J. Murphy 1, Rebecca D. Pentz 1, Chad Robichaux 1, Gerard Vong 1, Kevin Wack 2, and Neal W. Dickert 1*
doi : 10.1164/rccm.202106-1462le
Volume 204, Issue 12, pp: 1481–1484
An Association between Positive Airway Pressure Device Manufacturer and Incident Cancer? A Secondary Data Analysis
Tetyana Kendzerska 1,2,3*, Richard S. Leung 4,5, Mark I. Boulos 4,6, Daniel I. McIsaac 1,2,3, Brian J. Murray 4,6, Gregory L. Bryson 1,3, Robert Talarico 2,3, Atul Malhotra 7, Andrea S. Gershon 2,4,6, Constance Mackenzie 8,9, and Marcus Povitz 10
doi : 10.1164/rccm.202107-1734le
Volume 204, Issue 12, pp: 1484–1488
The Mystery of Futility of Appropriate Antibiotics for Coinfection in COVID-19
Daisuke Kasugai *, Naruhiro Jingushi , Norihiro Omote , Yuichiro Shindo , and Yukari Goto
doi : 10.1164/rccm.202107-1656le
Volume 204, Issue 12, pp: 1489
Reply to Kasugai et al.: The Mystery of Futility of Appropriate Antibiotics for Coinfection in COVID-19
Anahita Rouzé 1,2, Julien Labreuche 1,2, and Saad Nseir 1,2*; on behalf of all the authors
doi : 10.1164/rccm.202108-1846le
Volume 204, Issue 12, pp: 1489–1491
Initial Triple Combination Therapy for Intermediate-and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still Too Soon to Tell?
Qi Jin *, Lihua Guan *, Wenzhi Pan , and Daxin Zhou ‡
doi : 10.1164/rccm.202107-1622le
Volume 204, Issue 12, pp: 1491–1492
Treatment of Pulmonary Hypertension: Is Triple Therapy Necessarily Better than Monotherapy?
Xishi Sun 1,2*, Riken Chen 3,6,7*, Xiaoyun Yao 4*, Zhenzhen Zheng 2*, Manxia Wang 2*, Chaoyu Wang 5*, and Junfen Cheng 2‡
doi : 10.1164/rccm.202108-1965le
Volume 204, Issue 12, pp: 1492–1493
Reply to Jin et al. and to Sun et al.
Athénaïs Boucly 1,2,3*, Jason Weatherald 4*, Laurent Savale 1,2,3, Xavier Jaïs 1,2,3, David Montani 1,2,3, Marc Humbert 1,2,3, and Olivier Sitbon 1,2,3‡
doi : 10.1164/rccm.202107-1725le
Volume 204, Issue 12, pp: 1494–1495
Lung Cancer
Suzanne Lareau , Christopher Slatore , and Robert Smyth
doi : 10.1164/rccm.20411p21
Volume 204, Issue 12, pp: P21–P22
NO ABSTRACT
